Etienne Caron, PhD
Assistant ProfessorCards
About
Research
Overview
In the post-GWAS era, the HLA has been established as the region of the genome that is associated with the greatest number of human diseases, ranging from cancer and infectious diseases to autoimmune and neurodegenerative disorders.
HLA proteins present an extremely large and complex array of peptide fragments, which include both self and nonself peptides, collectively referred to as the human immunopeptidome.
CD8+ and CD4+ T cells interact with the human immunopeptidome through constant TCR recognition of both agonist and antagonist peptides, together shaping disease susceptibility, progression, or resistance. Nevertheless, very little is known about it from a systems-level and mechanistic perspective.
In this context, the overarching goal of the Caron Lab is to develop and apply mass spectrometry-based methods and systems immunology approaches to understand the generation, composition and dynamics of both the self and nonself immunopeptidome, as well as its interaction with CD8+ and CD4+ T cells, with the ultimate goal of innovating treatments and preventive strategies for a broad range of immune-related diseases.
To achieve this goal, the Caron Lab prioritizes the development of next-generation immunopeptidomics technologies, develops a systems immunopeptidomics framework to challenge the current T-cell activation paradigm, and collaborates with clinical investigators and researchers in the fields of autoimmunity, infectious diseases, and cancer to make an impact in vaccine design and T-cell-based immunotherapy.
Medical Research Interests
Public Health Interests
Academic Achievements & Community Involvement
Links
Media
(A) World map illustrating the ambition of profiling immunopeptidomes across human populations using advanced immunopeptidomics technologies. A microfluidic device for automated sample preparation and a mass spectrometer for data acquisition are shown as representative examples of technologies that will be further developed. (B) Schematic of the workflow to identify immunopeptidomic signatures of disease susceptibility/resistance to stratify patients and help personalize mitigation strategies in future pandemics. SARS-CoV-2 is used for illustrating the concept. In this example, viral peptides are isolated at population-scale from plasma samples (patient cohorts). Fictive bar plot of HLA-I-allele-specific self peptides in different organs (patient #1) and population-scale quantitative digital maps of soluble HLA-associated SARS-CoV-2 peptides from plasma samples are illustrated.